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Discussion
Dr Patricia Thistlethwaite (San Diego, Calif). The strength and
breadth of solid organ transplantation at the University of Minne-
sota have allowed for the creation of one of the largest groups of
transplant patients for the study of cardiovascular disease.
With data from the United Network for Organ Sharing sug-
gesting that kidney transplant patients survive on the average
between 10 and 23 years depending on whether the organ was
from a deceased or living donor and 25 years plus for an HLA
identically matched donor, and with long-term survivals for kid-
ney–pancreas transplants approaching 10 to 20 years, it is not
surprising that cardiac disease is developing in these individuals
over time. It is reassuring to see actual data about the safety of
cardiac surgery in patients with transplant allografts.
I have the following questions. What is the effect of immuno-
suppression on wound healing in cardiac surgery? Were the people
who had wound complications in your group receiving higher
doses of prednisone or FK506? Did infection develop in any
patients who were on a steroid-free protocol? Should patients be
tapered down or off steroids before their cardiac operation?
Dr John. Clearly the presence of immunosuppression did not
affect the incidence of mediastinal and leg wound infection or
multiorgan sepsis; however, an important immunosuppressant that
clearly affects wound healing is rapamycin. We do not have much
experience with this agent because none of these patients was
receiving it. However, that clearly is one immunosuppressive
agent that has been shown to markedly increase the risk of wound
dehiscence and multiple problems related to wound healing. All
these patients were on immunosuppression. I do not have the data
as to whether any of these patients were off steroids, but clearly
with the low incidence of wound infection in both groups I would
speculate that the presence of immunosuppression has not ad-
versely affected wound healing.
Dr Thistlethwaite. During cardiac surgery should all solid
organ transplant patients be treated the same? For example, do you
modify perfusion pressure for individuals with worse organ func-
tion, and would you suggest the routine use of aprotinin during
cases?
Dr John. My personal bias over the past 3 or 4 years has been
to use aprotinin with even mild to moderate degrees of renal
failure, maybe again based on some of the data to reduce the dose
of aprotinin if the creatinine concentration was increased. In view
of the recent report that all of us are aware of, I have refrained from
using aprotinin.24 That report, at least, shows that there has been
increased incidence of renal failure with aprotinin. Again, some-
thing that we do routinely is to tell the perfusionist to maintain a
higher perfusion pressure during cardiopulmonary bypass. It
would have been nice to have definitive data to show what that
pressure should be and in the event that those pressures were not
maintained if those patients suffer adversely from increased risk of
renal complications postoperatively.
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Dr Thistlethwaite. Was intra-aortic balloon pumping used in
any cardiac operations on kidney transplant patients? If so, from
which groin side was it placed? Was the fate of the allograft
different in any of these cases?
Dr John. Good question. It is something that we did not look
at but probably should.
Dr Thistlethwaite. Finally, when a valve replacement needs to
be performed in a patient with a kidney or liver transplant that will
require allograft biopsy in the future, what kind of valve do you
select and how do you manage their warfarin sodium (Coumadin)?
Dr John. I would treat that as I would with a nontransplant
recipient, again presenting the risks and benefits of a tissue versus
a mechanical valve. With increasing data that the tissue valves
have a longer freedom from degeneration as compared with 10
years ago, I now favor the use of tissue valves in renal transplant
patients to obviate the bleeding complications of biopsies and the
other adverse effects of warfarin. I would clearly recommend the
use of a tissue valve in these patients.
Dr David Follette (Sacramento, Calif). I too enjoyed your
presentation. I am still bothered by the fact that you included
patients with failed renal allografts in your analysis. The real
question is, in patients with functioning transplants, does cardiac
surgery have an adverse effect on those transplants? Those patients
were all receiving dialysis. Even if they were on a low dose of
immunosuppression, at least the way my anticipation in reading
your abstract was, I wanted to know what happened with patients
who had transplants and you reduce your n size down to 40 from
70. Perhaps you could tell us in a little bit more detail why you
included patients who had failed transplants in your analysis.
Dr John. It was something that we grappled about and we finally
decided to include them. As you know, most if not all of these patients
are on immunosuppression. I was initially surprised that patients with
failed allografts are on immunosuppression, and the reason that I
obtained on discussion with one of the renal transplant physicians was
twofold. One is that the presence of immunosuppression in a patient
with a failed renal allograft will prevent the development of anti-HLA
antibodies. Their development would be a contraindication for a
second renal transplant, which is always considered in a patient with
a failed allograft. The second reason for having maintenance immu-
nosuppression even though they have chronic failed grafts is to
prevent the occurrence of acute rejection, which can still happen in a
failed organ. An acute rejection could make these patients especially
sick. For both of these reasons they are on maintenance immunosup-
pression. That is why we included patients with failed allografts with
the renal transplant. The good news is that even if we took that away,
the message is still the same. The operative mortality is low and
morbidity is comparable except for a higher incidence of renal dys-
function. Those were the reasons that we clumped them together.
Dr Michael Davidson (Boston, Mass). Given your excellent
results and also your large patient population, I would be interested
to know whether there are any plans to do any kind of comparison
between surgical revascularization as you have done and percuta-
neous revascularization. That might be an interesting question in
terms of how these patients fare with percutaneous coronary in-
terventions, not only in terms of their transplant but also in terms
of what their revascularization success is over time comparing
surgical versus percutaneous in this particular patient population.
Dr John. I will answer that very briefly. It is hard to make a
comparison from this study. About 40% of our patients who under-
went CABG with a renal transplant had previous coronary interven-
tions. From the larger United States Renal System database, even
though the initial operative mortality was higher in renal transplant
patients than in those with percutaneous coronary intervention, long-
term survival was significantly better with surgical revascularization.
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